Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic Review

被引:3
|
作者
Gasoyan, Hamlet [1 ,6 ]
Fiala, Mark A. [2 ]
Doering, Michelle [3 ]
Vij, Ravi [2 ]
Halpern, Michael [4 ]
Colditz, Graham A. [5 ]
机构
[1] Cleveland Clin, Primary Care Inst, Ctr Value Based Care Res, Dept Internal Med & Geriatr, Cleveland, OH USA
[2] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO USA
[3] Washington Univ, Sch Med, Bernard Becker Med Lib, St Louis, MO USA
[4] NCI, Healthcare Delivery Res Program, Bethesda, MD USA
[5] Washington Univ, Sch Med, Dept Surg, Div Publ Hlth Sci, St Louis, MO USA
[6] Cleveland Clin, Primary Care Inst, Ctr Value Based Care Res, Dept Internal Med & Geriatr, 9500 Euclid Ave,G10, Cleveland, OH 44195 USA
来源
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷 / 11期
关键词
Health equity; Health insurance; Hematologic malignancies; Race; Social determinants of health; HEMATOPOIETIC-CELL TRANSPLANTATION; HEALTH-CARE COSTS; RACIAL DISPARITIES; ELDERLY-PATIENTS; WHITE PATIENTS; SURVIVAL; POPULATION; BLACK; CHEMOTHERAPY; MANAGEMENT;
D O I
10.1016/j.clml.2023.08.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We performed a systematic review of the literature investigating the demographic and insurance-related factors linked to disparities in multiple myeloma (MM) care patterns in the United States from 2003 to 2021. Forty-six observational studies were included. Disparities in MM care patterns were reported based on patient race in 76% of studies (34 out of 45 that captured race as a study variable), ethnicity in 60% (12 out of 20), insurance in 77% (17 out of 22), and distance from treating facilit y, urbanicit y, or geographic region in 62% (13 out of 21). A smaller proportion of studies identified disparities in MM care patterns based on other socioeconomic characteristics, with 36% (9 out of 25) identi-fying disparities based on income estimate or employment status and 43% (6 out of 14) based on language barrier or education-related factors. Sociodemographic characteristics are frequently associated with disparities in care for individ-uals diagnosed with MM. There is a need for further research regarding modifiable determinants to accessing care such as insurance plan design, patient out-of-pocket costs, preauthor ization cr iter ia, as well as social determinants of health. This information can be used to develop actionable strategies for reducing MM health disparities and enhancing timely and high-quality MM care.
引用
下载
收藏
页码:E420 / E427
页数:8
相关论文
共 50 条
  • [31] Effect of bortezomib on the treatment of multiple myeloma: a systematic review protocol
    Cantadori, Lucas Oliveira
    Gaiolla, Rafael Dezen
    Nunes-Nogueira, Vania dos Santos
    BMJ OPEN, 2022, 12 (06):
  • [32] A systematic review of economic evaluations of treatment regimens in multiple myeloma
    Asrar, Mir Mahmood
    Lad, Deepesh P.
    Prinja, Shankar
    Bansal, Dipika
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (04) : 799 - 809
  • [33] Time to Take Stock: A Meta-Analysis and Systematic Review of Analgesic Treatment Disparities for Pain in the United States
    Meghani, Salimah H.
    Byun, Eeeseung
    Gallagher, Rollin M.
    PAIN MEDICINE, 2012, 13 (02) : 150 - 174
  • [34] Racial and Ethnic Disparities in Hepatocellular Carcinoma Treatment Receipt in the United States: A Systematic Review and Meta-Analysis
    Wagle, Nikita Sandeep
    Park, Sulki
    Washburn, David
    Ohsfeldt, Robert
    Kum, Hye-Chung
    Singal, Amit G.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (04) : 463 - 470
  • [35] ETHNIC AND RACIAL DISPARITIES IN PROGRESSION OF MULTIPLE SCLEROSIS IN THE UNITED STATES: A LITERATURE REVIEW
    Gerges, M.
    Cao, R.
    Desai, K.
    Hiranandani, A.
    Jin, C.
    Kang, S.
    Lee, S.
    Afghani, B.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2024, 72 (01) : 165 - 168
  • [36] Racial Disparities in Treatment Utilization for Multiple Myeloma
    Fiala, Mark A.
    Dukeman, James
    Wildes, Tanya M.
    BLOOD, 2016, 128 (22)
  • [37] Racial disparities in treatment use for multiple myeloma
    Fiala, Mark A.
    Wildes, Tanya M.
    CANCER, 2017, 123 (09) : 1590 - 1596
  • [38] Patterns and Predictors of Initiation of Intravenous Bisphosphonates Among Patients with Multiple Myeloma in the United States
    McGrath, Leah J.
    Hernandez, Rohini K.
    Overman, Robert
    Reams, Diane
    Liede, Alexander
    Brookhart, M. Alan
    BLOOD, 2017, 130
  • [39] Risk patterns of multiple myeloma in Los Angeles County, 1972–1999 (United States)
    Mulugeta Gebregziabher
    Leslie Bernstein
    Yaping Wang
    Wendy Cozen
    Cancer Causes & Control, 2006, 17 : 931 - 938
  • [40] Adverse event and outcome patterns in patients with advanced multiple myeloma in the United States.
    Richter, Joshua Ryan
    Yeaw, Jason
    Shah, Drishti
    Anupindi, Ruthwik
    Kudaravalli, Suneel
    Zavisic, Stojan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)